Fucoidan attenuates metabolic dysfunction-associated fatty liver disease in mice and is associated with gut microbiota remodeling and AMPK/PPARγ signaling
- 1Department of Gastroenterology, The Affiliated Hospital of Qingdao University
- 2Department of Gastroenterology, Qingdao Cardiovascular Hospital
Abstract
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing metabolic disorder closely linked to gut micro biota dysbiosis and impaired gut–liver communication. Dietary interventions targeting the gut micro biota represent a promising strategy for MAFLD management. Fucoidan (FUC), a marine-derived bioactive polysaccharide with limited host digestibility, is primarily metabolized by intestinal microorganisms. However, whether FUC protects against MAFLD in association with micro biota-mediated mechanisms remains incompletely understood.
Methods: C57BL/6J mice were fed a high-fat diet (HFD) for 14 weeks, while the FUC intervention group received FUC by oral gavage at a dose of 200 mg/kg/day over the same period. Body weight, adiposity, serum lipid and glucose metabolism, liver function, and histopathology were evaluated. Gut micro biota composition was analyzed by 16S rRNA sequencing, and serum metabolomic profiling was performed using untargeted metabolomics combined with KEGG enrichment and Spearman correlation analyses.
Results: FUC supplementation markedly attenuated HFD-induced obesity, impaired glucose tolerance, dyslipidemia, hepatic steatosis, and HFD-associated alterations in intestinal barrier-related structural and molecular features. Microbiome analysis revealed that FUC administration was associated with changes in gut microbial diversity and community composition, including altered relative abundances of Akkermansia, Adlercreutzia , and Dubosiella . Metabolomic analysis further demonstrated changes in systemic metabolic profiles, particularly tricarboxylic acid (TCA) cycle-related metabolites. Correlation analyses identified associations among microbial features, circulating metabolites, and MAFLD-related phenotypes. FUC administration was associated with gut micro biota remodeling and altered hepatic AMPK/PPARγ signaling, accompanied by improved metabolic homeostasis and reduced hepatic inflammation.
Conclusion: Our findings demonstrate that FUC alleviates HFD-induced MAFLD and is associated with remodeling of the gut micro biota, alterations in circulating TCA cycle-related metabolites, and changes in hepatic AMPK/PPARγ signaling. Integrated analyses suggest a potential gut micro biota–metabolism–liver regulatory network associated with the hepato protective effects of FUC. These findings provide potential mechanistic insights into the beneficial effects of FUC and support further investigation of marine-derived polysaccharides as dietary strategies for metabolic disease management.
Related
- Gut virome remodeling after fecal microbiota transplantation is associated with virus-bacteria co-variation and metabolic response in obesity and type 2 diabetes.
- Small-Intestinal Motility Interrelates With Fecal Microbiota, Metabolites and Metabolic Tissue Gene Expression in Metabolic Dysfunction-Associated Steatotic Liver Disease
- Lactiplantibacillus plantarum-Fermented Broccoli Attenuates Metabolic Dysfunction and Improves Skeletal Muscle Quality in High-Fat/High-Fructose Diet-Fed Mice.
- Chronic oral exposure to didecyldimethylammonium chloride induces region-specific intestinal dysfunction and gut microbiota remodeling in mice
- Antipsychotic-Induced Remodeling of the Gut Microbiota: Drug-Specific Patterns and Molecular Links to Metabolic Adverse Effects.
BibTeX
@article{li2026fucoidan,
title = {{Fucoidan attenuates metabolic dysfunction-associated fatty liver disease in mice and is associated with gut microbiota remodeling and AMPK/PPARγ signaling}},
author = {Yukun Li and Mengchen Shan and Qinxin Liu and Xue Jing and Zan Wang and Tao Mao and Xingsi Qi and Bin Cao and Zibin Tian and Rongshuang Han},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1936901},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1936901/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Fucoidan attenuates metabolic dysfunction-associated fatty liver disease in mice and is associated with gut microbiota remodeling and AMPK/PPARγ signaling
AU - Yukun Li
AU - Mengchen Shan
AU - Qinxin Liu
AU - Xue Jing
AU - Zan Wang
AU - Tao Mao
AU - Xingsi Qi
AU - Bin Cao
AU - Zibin Tian
AU - Rongshuang Han
PY - 2026
DA - 2026/10/27
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1936901
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1936901/full
AB - Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing metabolic disorder closely linked to gut micro biota dysbiosis and impaired gut–liver communication. Dietary interventions targeting the gut micro biota represent a promising strategy for MAFLD management. Fucoidan (FUC), a marine-derived bioactive polysaccharide with limited host digestibility, is primarily metabolized by intestinal microorganisms. However, whether FUC protects against MAFLD in association with micro biota-mediated mechanisms remains incompletely understood. Methods: C57BL/6J mice were fed a high-fat diet (HFD) for 14 weeks, while the FUC intervention group received FUC by oral gavage at a dose of 200 mg/kg/day over the same period. Body weight, adiposity, serum lipid and glucose metabolism, liver function, and histopathology were evaluated. Gut micro biota composition was analyzed by 16S rRNA sequencing, and serum metabolomic profiling was performed using untargeted metabolomics combined with KEGG enrichment and Spearman correlation analyses. Results: FUC supplementation markedly attenuated HFD-induced obesity, impaired glucose tolerance, dyslipidemia, hepatic steatosis, and HFD-associated alterations in intestinal barrier-related structural and molecular features. Microbiome analysis revealed that FUC administration was associated with changes in gut microbial diversity and community composition, including altered relative abundances of Akkermansia, Adlercreutzia , and Dubosiella . Metabolomic analysis further demonstrated changes in systemic metabolic profiles, particularly tricarboxylic acid (TCA) cycle-related metabolites. Correlation analyses identified associations among microbial features, circulating metabolites, and MAFLD-related phenotypes. FUC administration was associated with gut micro biota remodeling and altered hepatic AMPK/PPARγ signaling, accompanied by improved metabolic homeostasis and reduced hepatic inflammation. Conclusion: Our findings demonstrate that FUC alleviates HFD-induced MAFLD and is associated with remodeling of the gut micro biota, alterations in circulating TCA cycle-related metabolites, and changes in hepatic AMPK/PPARγ signaling. Integrated analyses suggest a potential gut micro biota–metabolism–liver regulatory network associated with the hepato protective effects of FUC. These findings provide potential mechanistic insights into the beneficial effects of FUC and support further investigation of marine-derived polysaccharides as dietary strategies for metabolic disease management.
SN - 1664-302X
ER -